Jevtana

Cabazitaxel, the active ingredient in Jevtana, is a taxane presented as a 20 mg per vial injectable solution for intravenous use. It is indicated for metastatic castration‑resistant prostate cancer in patients whose disease has progressed after docetaxel chemotherapy.

GNH USA supplies Jevtana as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, complying with EU quality standards. The company provides regulated cold‑chain logistics and supports import documentation for global distribution. Clients benefit from consistent product quality, traceability and responsive technical support.

Cabazitaxel is a taxane chemotherapy used in the treatment pathway for advanced prostate cancer.

Metastatic castration‑resistant prostate cancer after docetaxel therapy: provides an additional line of therapy to improve disease control.

Cabazitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often accompanied by vomiting. - Diarrhea: loose stools that may lead to dehydration.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary embolism: blood clot in the lungs requiring urgent care. - Hepatic toxicity: elevated liver enzymes or liver failure. - Cardiac events: arrhythmias or myocardial infarction. - Severe diarrhea leading to electrolyte imbalance.

Before initiating Jevtana therapy, clinicians should evaluate several safety considerations.

Pregnancy: Category D – avoid use unless benefits outweigh risks. Breastfeeding: not recommended due to potential drug excretion in milk. Renal impairment: assess kidney function and adjust monitoring. Hepatic impairment: consider dose modification and monitor liver enzymes. Concomitant myelosuppressive therapy: increase frequency of blood count monitoring. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure. - Concurrent myelosuppressive agents: heightened risk of severe neutropenia. - Live vaccines: increased infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs. - Diuretics: watch electrolyte balance during fluid shifts.